[ad_1]
Benefiting from a slew of market takeover news and frequent good news about vaccines, the US stock market ended its worst weekly decline since March. The main indices opened higher on Monday (14). The Dow Jones industrial average opened 182 points or 0.66. %, Apple led earnings.
The Nasdaq index opened 153 points or 1.41% on Monday, the S&P 500 index was up nearly 1% and the rate was up 2.2%. Huida led the way up.
In the news of the merger, after people familiar with the matter revealed that Oracle is likely to be the winner of the TikTok acquisition, Oracle (ORCL-US) opened 6.7% and subsequently suspended operations in waiting for more information.
On Sunday (13) it was announced that it had acquired TikTok, which broke with Microsoft (MSFT-US), and opened slightly with a rise of 0.74%.
Huida (NVDA-US) led the rate hike in half on Monday, rising more than 7% in early trading. The company announced that it has reached an agreement with Softbank to acquire the ARM chip design company (ARM) for US $ 40 billion.
In response to strong demand for e-commerce during the epidemic, Amazon (AMZN-US) announced that it will hire 100,000 more employees in the United States and Canada this year, spurring its share price to rise 1.9% in the first operations. Open trends for other tech stocks are as follows: Apple (AAPL-US) rose 1.8%, Facebook (FB-US) rose 1.2%, and Google’s parent company Alphabet (GOOGL-US) rose. 1%.
In the news section on vaccines, Pfizer (PFE-US) CEO Albert Bourla said in an interview on Sunday (13) that it is expected to know if the company’s candidate vaccines are effective before the end of October. If the vaccine is approved by the FDA, it will be distributed to the American public before the end of the year. Billions of COVID-19 vaccines. Pfizer opened 1%.
In addition, after being released by the British competent authority, the University of Oxford announced on Saturday (12) that it would restart a clinical trial of vaccines in cooperation with AstraZeneca, which was forced last week due to a suspected adverse reaction from an evaluator. . Aborted.
As of Monday (14) 21 o’clock, Taipei time:
- The Dow Jones index rose 182.01 points or 0.66%, temporarily reporting 27847.65 points.
- Nasdaq climbed 153.01 points, or 1.41%, to 11006.56 points temporarily
- S&P 500 rose 32.26 points, or 0.97%, temporarily to 3,373.23 points
- Commissions and a half rose 47.39 points or 2.22%, temporarily to 2,183.76 points
- TSMC ADR rises 2.18% to $ 80.54 per share
- Yield on 10-year US Treasuries fell to 0.661%
- New York light crude fell 0.40% to $ 37.18 a barrel
- Brent crude oil fell 0.45% to $ 39.65 a barrel
- Gold rose 0.91% to $ 1965.70 an ounce
- The US dollar index fell 0.45% to 93.92 points
Focus actions:
Huida (NVDA-US) rose 7.16% to US $ 521.40 in early trading.
Huida announced on Sunday (13) that it had reached a definitive agreement with SoftBank Group to acquire the integrated circuit design company ARM (ARM) at a price of 40,000 million dollars. Because the transaction still requires regulatory approvals from China, the United Kingdom, the United States and the European Union, it is expected that it will require 18 months to complete the final transaction.
According to media reports, Huida will acquire Anmou with $ 21.5 billion in stock and $ 12 billion in cash, including a $ 2 billion signing bonus. Based on Anmou’s future business performance, SoftBank will receive up to $ 5 billion in cash and shares. You can get Huida shares worth US $ 1.5 billion.
Oracle (ORCL-US) was up 6.67% in early trading to $ 60.80, then suspended trading pending news.
Microsoft issued a statement on Monday (14) stating that Bytedance had rejected the company’s proposal to acquire the TikTok business in the United States, and the merger between the two parties was officially announced. At the same time, foreign media quoted people familiar with the matter as saying that the Bytedance Project chose Oracle as the company’s “technical partner” in the United States.
Immunomedics (IMMU-US) was up 105.44% to US $ 86.80 in early trading.
The American pharmaceutical giant Gilead (GLID-US) announced on Sunday (13) that it will spend 21 billion dollars to acquire the biotechnology company Immunomedics to help the company enter the cancer drug market.
It is understood that Gilead agreed to purchase US $ 88 in cash per share, a premium of 108% to Immunomedics closing price on Friday (11). Daniel O’Day, CEO of Gilead, said this acquisition will help the company accelerate its entry into the cancer field and realize its vision of diversifying its product portfolio.
Daily key economic data:
Not
Wall Street Analysis:
Sebastien Galy, Senior Strategist at Nordea Investment Funds, said: “As the US and European economies are stimulated by strong monetary policies, the market is likely to have surprises in the fourth quarter. We should seize the market opportunity to buy in the falls “.
The Federal Reserve Committee (Fed) will hold an interest rate meeting in September this Thursday (17). Nomura Securities economists expect the Fed to not announce any major monetary policy, but the meeting is still important because the Fed will release its latest economic forecast.
The Nomura Securities economist said: “We believe the September interest rate meeting will discuss key long-term issues, and important policy announcements will still have to wait until the end of this year.”
[ad_2]
